Eloxx Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
April 22, 2019 09:37 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Participate in the 2019 5th Annual SunTrust Robinson Humphrey (STRH) Life Sciences Summit on May 7, 2019
April 15, 2019 13:15 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the European Cystic Fibrosis Society (ECFS) Basic Science Conference
March 27, 2019 09:00 ET
|
Eloxx Pharmaceuticals
ELX-02 shows significant increases in CFTR protein expression and localization correlating with functional activity in Cystic Fibrosis patient-derived organoids bearing CFTR nonsense mutations In...
Eloxx Pharmaceuticals to Present at the Guggenheim Rare Disease & Genomic Medicines Day on April 2, 2019
March 20, 2019 12:19 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., March 20, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update
March 08, 2019 07:00 ET
|
Eloxx Pharmaceuticals
Eloxx announces the hiring of Dr. Susan Schneider as SVP Ophthalmology to lead the development of its rare inherited retinal disease programs Abstract accepted for presentation at European Cystic...
Eloxx Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019
March 05, 2019 09:08 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Announces Participation in the HIT-CF Project on Cystic Fibrosis
February 26, 2019 16:02 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Present at the Barclays Global Healthcare Conference on March 14, 2019
February 20, 2019 16:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019
February 19, 2019 07:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Friday, March 1, 2019
February 14, 2019 08:40 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...